A 2026 randomized trial suggests that diets guided by food-sensitivity testing may outperform generic elimination diets for irritable bowel syndrome — with a few important caveats.
What the study found
A double-blind, sham-controlled trial from Sheba Medical Center, published in Gastroenterology Report (2026), looked at 68 patients with IBS (diarrhea-predominant or mixed type) enrolled between 2020 and 2022.
Patients were randomized into two groups for eight weeks:
- Alcat-guided diet: an elimination diet personalized to each patient based on leukocyte activation testing (a blood test that flags foods triggering white blood cell responses)
- Sham diet: a diet structurally similar in restrictiveness, but not matched to the patient’s own test results
Neither the patients nor the clinicians assessing outcomes knew who got which diet. The primary endpoint was a 50-point or greater reduction on the IBS Symptom Severity Scale (IBS-SSS), a validated measure of symptom burden, with secondary measures including the IBS Global Improvement Scale.
The results favored the Alcat-guided group across the board, with a reported 85.7% achieving a meaningful clinical response. It’s the largest trial of its kind to date, building on earlier research from a Yale-affiliated group.
Why this matters
Most diet studies for IBS struggle with a fundamental problem: it’s nearly impossible to blind a diet. This trial’s sham-controlled design — where the control diet was equally restrictive but not personalized — is about as rigorous as nutrition research gets. That makes the findings harder to dismiss than the typical observational claims around food-sensitivity testing.
A balanced view
As with any single study, context matters:
- Small sample: 68 patients is modest, even as the largest trial of its type.
- One trial: Replication in larger, independent studies is needed before this becomes standard practice.
- The test itself remains debated: Leukocyte activation testing for food sensitivities is not endorsed by major allergy societies, which consider the evidence base insufficient. This trial is a step toward answering that question — not the final word.
What this means for you
If you live with IBS and feel like your diet is working against you, a structured, personalized approach to identifying trigger foods may be worth discussing — alongside established IBS management strategies.
Dr. Subramani treats IBS via telemedicine for patients across Missouri and Illinois, and in person in Sikeston, MO.
This article summarizes peer-reviewed research for educational purposes and is not medical advice. Study: Sheba Medical Center, published in Gastroenterology Report (2026).
